A new study sheds light on why some patients with the most aggressive form of ovarian cancer respond better to treatment than others. Tumors positive for a molecule called MHC class II are linked to ...

Westlake Therapeutics (Hangzhou) Co. Ltd. and affiliated organizations have reported the design and preclinical characterization of novel erythrocytes conjugated to major histocompatibility complex ...

Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...

A new technology to increase visibility of cancer cells to the immune system using CRISPR has been developed, and could lead to a new way to treat cancer. Major histocompatibility complex (MHC) class ...

Peptides that bind major histocompatibility complex (MHC) class I molecules act as chemosensory signals in a region of the brain thought to be important in chemosensory communication, according to a ...

A new technology to increase visibility of cancer cells to the immune system using CRISPR has been developed, and could lead to a new way to treat cancer. Major histocompatibility complex (MHC) class ...

Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.

Researchers at The University of Texas MD Anderson Cancer Center have uncovered a gene on the Y chromosome that is upregulated in KRAS-mutated colorectal cancer (CRC), increasing tumor cell ...

The adaptive immune system is an antigen-specific structure that discriminates non-self molecules through the recognition of peptide antigens using receptor interactions between T-cells and ...